Connect
MJA
MJA

Familial hypercholesterolaemia in Australia: new insights and developments

Ian R Hamilton-Craig and Gerald F Watts
Med J Aust 2013; 198 (2): 72-73. || doi: 10.5694/mja12.11467
Published online: 4 February 2013

A model of care is in place but the challenge of early detection remains

Familial hypercholesterolaemia (FH) is the most common and serious type of inherited hyperlipidaemia. It causes premature atherosclerotic cardiovascular disease (CVD), in particular coronary heart disease (CHD), bringing forward the onset of CVD by one to four decades.1

  • Ian R Hamilton-Craig1
  • Gerald F Watts2

  • 1 Griffith University School of Medicine, Gold Coast, QLD.
  • 2 School of Medicine and Pharmacology, University of Western Australia, Perth, WA.

Correspondence: ihcgriffith@gmail.com

Competing interests:

Ian Hamilton-Craig has received honoraria for consulting and lectures from the following pharmaceutical companies: Sanofi, Abbott, Merck Sharp & Dohme, Novartis, AstraZeneca, Pfizer, Amgen. Gerald Watts has received honoraria for consulting and lectures from the following pharmaceutical companies: Sanofi, Genzyme, Amgen, Abbott, Johnson & Johnson, Merck Sharp & Dohme, Novartis, AstraZeneca, GlaxoWelcome, Pfizer.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.